CompletedNot Applicable

Use of Belatacept to Delay Tacrolimus Initiation in Kidney Transplant Patients With Delayed Graft Function

United States67 participantsStarted 2022-08-22

Plain-language summary

Evaluate the impact of one dose of belatacept in patients with Delayed Graft Function(DGF) on their time to renal recovery and corresponding rates of patient and graft survival, rejection, and incidence of BK virus(BKV), Epstein-Barr Virus(EBV) and/or cytomegalovirus (CMV) infections.

Who can participate

Age range18 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥18 years * Received living or deceased donor kidney transplant during study period * Documented DGF Exclusion Criteria: * Multiple organ transplant * Recipients with acute rejection present on first biopsy evaluation before first belatacept dose * Recipients with a first dose of belatacept after index discharge or tacrolimus initiation

What they're measuring

Time to renal recovery

Timeframe: 1 year

post-transplant outcome

Timeframe: 1 year

Trial details

NCT IDNCT06091995

SponsorMethodist Health System

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-07-07

View on ClinicalTrials.gov More Use of Belatacept in Kidney Transplant Patients trials